Our pipeline includes potential cancer therapies targeting malignant cells both directly and through modulation of the tumor microenvironment. Our Verastem Oncology programs include:

  • RAF/MEK inhibitor (VS-6766)
  • Focal adhesion kinase (FAK) inhibitor (defactinib)

These studies are investigating treatments or outcomes that have not received approval from a Health Authority. There is no guarantee that the outcome of these studies will result in approval.

 

Verastem Oncology also accepts proposals for preclinical research collaborations. For more information, please reach out to us at research@verastem.com